BiomedicineNews.net

Biomedicine Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Immunotherapy"

A new type of immunotherapy in which dendritic cells are tricked into action against cancer when they are exposed to harmless pieces of viruses and bacteria is described in the journal Cancer Research ...


Selective T cell stimulation could help improve treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, or juvenile diabetes. and cancer. " Our study shows that different ...


Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer.These vari ...


Researchers from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted ...


Lung cancer is the number one cause of cancer mortality globally and has an estimated incidence of 1.3 million new cases every year. Approximately 80–85% of the newly diagnosed cases of lung cancer ar ...


City of Hope researchers at Duarte, California ( U.S. ) have reported on the successful treatment of a patient with recurrent multifocal glioblastoma using CAR-T therapy, a type of immunotherapy, to e ...


Chimeric antigen receptor ( CAR ) T cell immunotherapy has demonstrated profound results in hematologic malignancies but clinical efficacy in the solid tumor setting has not been observed. Barriers t ...


A novel approach to immunotherapy developed by researchers at the National Cancer Institute ( NCI ) has led to the complete regression of breast cancer in a patient who was unresponsive to all other t ...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Yescarta ( Axicabtagene ciloleucel ) for the treatment of adult patients with relapsed or refractory follicular lympho ...


The FDA ( U.S. Food and Drug Administration ) has approved Abecma ( Idecabtagene vicleucel; Ide-cel ) as the first B-cell maturation antigen ( BCMA )-directed chimeric antigen receptor ( CAR ) T cell ...


The European Commission ( EC ) has granted Conditional Marketing Authorization for Abecma ( Idecabtagene vicleucel; Ide-cel ), a first-in-class B-cell maturation antigen ( BCMA )-directed chimeric ant ...